European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 63-69 , January 2009

INR variability in atrial fibrillation: A risk model for cerebrovascular events

  • Philippe Amouyel

      Affiliations

    • Inserm U744, Lille, France
    • Université Lille 2, Lille, France
    • Institut Pasteur de Lille, Lille, France
    • ,
  • Patrick Mismetti

      Affiliations

    • Hôpital Bellevue, Saint Etienne, France
    • ,
  • Lars K. Langkilde

      Affiliations

    • Formerly AstraZeneca R&D, Mölndal, Sweden
    • Corresponding Author InformationCorresponding author. COWI-MUUSMANN, Nytorv 2, DK-6000 Kolding, Denmark. Tel.: +45 76 33 86 77; fax: +45 24 63 68 82.
    • ,
  • Guillermo Jasso-Mosqueda

      Affiliations

    • AREMIS, Neuilly, France
    • ,
  • Karin Nelander

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • ,
  • Hervé Lamarque

      Affiliations

    • Formerly AstraZeneca, Rueil Malmaison, France

Received 19 October 2007 ,Revised 23 January 2008 ,Accepted 27 April 2008.

References 

  1. Gales CL, Massol J, Begaud B. L'évaluation de l'impact d'un médicament sur la santé des populations et la Santé Publique: Projet pour discussion. Direction Generale De La Santé. January 2002. Available at: http://www.rees-france.com/IMG/pdf/DOC_evaluation_dgs.pdf. Downloaded 15 December 2005.
  2. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet. 2002;31:711–715
  3. Gurewich V. Ximelagatran — promises and concerns. JAMA. 2005;293:736–739
  4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501
  5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation — executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:700–752
  6. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol. 2003;41:1633–1652
  7. Scardi S, Mazzone C. New operative models for the management of anticoagulant prophylaxis. Monaldi Arch Chest Dis. 2002;58:64–69(Italian)
  8. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low?. Clin Cardiol. 2002;25:447–454
  9. Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349:1019–1026
  10. Ansell J, Hollowell J, Pengo V, Martinez-Brotons F, Caro J, Drouet L. Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM). J Thromb Thrombolysis. 2007;23:83–91
  11. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236–239
  12. Azar AJ, Deckers JW, Rosendaal FR, van Bergen PF, van der Meer FJ, Jonker JJ, et al. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemost. 1994;72:347–351
  13. Diener HC. Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies. Cerebrovasc Dis. 2006;21:279–293
  14. Halperin JL Executive Steering Committee on behalf of the SPORTIF III and V Investigators. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J. 2003;146:431–438
  15. Greene WH. Econometric analysis. New York: Macmillan Publishing Company; 1993;
  16. Chernick MR. Bootstrap methods — a practitioner's guide. Chichester, UK: John Wiley & Sons; 1999;
  17. Olsson SB Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691–1698
  18. Kaatz S, White HD, Gruber M, Albers GW. Outcomes for ximelagatran compared with warfarin according to INR control: results from SPORTIF III and V atrial fibrillation trials. Blood. 2005;106:Abstract 902
  19. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis. 2000;9:283–292
  20. Odén A, Fahlén M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ. 2002;325:1073–1075
  21. Agence Française de Securité Sanitaire des Produits de Santé. Les médicaments antivitamine K (AVK) Suivi biologique du traitement par antivitamine K. Étude de 2000. Available at: http://agmed.sante.gouv.fr/htm/10/avk/etude3.htm. Accessed 12 December 2005.
  22. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:204S–233S
  23. Agence Française de Securité Sanitaire des Produits de Santé. Les médicaments antivitamine K (AVK). Hémorragies du système nerveux central associées à un traitement AVK: analyse des facteurs de risque. Available at: http://agmed.sante.gouv.fr/htm/10/avk/etude1.htm. Accessed 12 December 2005.

PII: S0953-6205(08)00136-2

doi: 10.1016/j.ejim.2008.04.005

European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 63-69 , January 2009

Article Tools

* Image Usage & Resolution